A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2018
At a glance
- Drugs Tazemetostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 26 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 27 Aug 2018 Planned primary completion date changed from 1 Sep 2020 to 30 Sep 2020.
- 08 Jul 2018 Planned primary completion date changed from 31 Jan 2020 to 1 Sep 2020.